Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06160635

D-SOLVE Cohorts (Cohort a and B)

Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).

This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

HDV Chronic Liver Disease Digestive System Diseases HDV Infection Hepatitis Hepatitis D Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology, Hanover, Germany

Loading trial locations.

About this study

The D-SOLVE consortium ("Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D"), aims for an unbiased screening of a large multicenter cohort of well-defined HDV-infected patients to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments.

The D-SOLVE cohorts will be collected retrospectively as well as prospectively with clinical and virological data and biomaterial for the biomarker analysis. The aim of the cohorts is as following:

Cohort A: To define the demographic, clinical, virological, and immunological features of a large cross-sectional cohort of 750 untreated and treated HDV patients at 4 EU centers. To compare these features among patients with different origin, gender, disease severity and treatment. To collect biological material to generate translational studies, aimed to better understand pathogenesis, natural history and treatment response.

Cohort B: To identify histological and immunological features that are associated with fibrosis progression and clinical complications in patients with chronic HDV infection.

The D-SOLVE consortium has received funding from the Horizon 2020 EU Horizon Call "Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)" of the European Union (grant agreement No 101057917). The consortium is coordinated by Hannover Medical School (MHH) and the Centre for Individualised Infection Medicine (CiiM). Other partners are:

  • Helmholtz-Zentrum für Infektionsforschung (HZI), Germany
  • Institut national de la santé et de la recherche médicale (INSERM)
  • Karolinska Institutet (KI), Sweden
  • Karolinska University Hospital / Region Stockholm (KUH), Sweden
  • Policlinico of Milan (PFM), Italy
  • National Institute for Infectious Diseases "Prof Dr Matei Balș" (INBIMB), Romania
  • Helmholtz-Zentrum für Informationssicherheit (CISPA), Germany

The Cohorts and the biomarker screening are part of the EU-funded D-SOLVE Consortium.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Anti-HDV positive
  • ≥18 years old
  • Sex: m/f/d
  • Informed consent for prospective procedures

Exclusion criteria

  • Anti-HDV negative

Treatment and study plan

Primary outcomes

  1. Biosample Screening

    Time frame: 3 years

    Identification of biomarkers that are associated with disease control, progression and treatment response by a multiomics approach that includes the investigation of: - the genome by the Illumina Infinium Global Screening array - the transcriptome by RNA-sequencing and single-cell RNA-sequencing (subset of samples) - the proteome by the Olink technology (high throughput proximity extension assay) - the metabolome by HPLC 1H-NMR (~2k metabolite features) - the methylome (Illumina 850k array) - immune phenotypes by high dimensional spectral flow cytometry - Spatial transcriptomics and multiplex imaging of HDV-patient liver biopsies

Secondary outcomes

  1. Definition of the demographic, clinical and virological features of the cohort.

    Time frame: 3 years

    Identification of immunological determinants of liver disease progression, viral control and treatment response by - scRNA/ATAC sequencing of Ag-specific T cells, NK cells and MAIT cells (PBMC) - spatial multiomics with feature barcoding technology of liver core biopsies - Validation of findings by 29-color flow cytometry, hepatoma HDV infection system and respective mouse models

  2. Identification of virological and immunological features and characteristics that relate to disease severity and treatment response.

    Time frame: 3 years

    Establishment of a computational model to predict immune responses and disease phenotype

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Kahlhöfer

CONTACT

[email protected]

Petra Dörge

CONTACT

[email protected]

+495115326057

Sponsors and collaborators

Lead sponsor

Hannover Medical School

Other

Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  • Helmholtz Centre for Infection Research
  • Karolinska Institutet
  • Karolinska University Hospital
  • National Institute of Infectious Diseases Matei Bals

Registry information

Acronym: HDV750

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Dec 7, 2023
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.